2013 American Transplant Congress
Effects of Locoregional Treatment and “Downstaging” on Long-Term Post-Liver Transplant Outcomes for Patients with Hepatocellular Carcinoma
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Research, UNOS, Richmond, VA
IntroductionLocoregional therapy (LRT) has been used to stabilize tumor growth for patients with hepatocellular carcinoma (HCC) waiting for liver transplantation (LT). However, the long-term effects…2013 American Transplant Congress
Geographic Heterogeneity in Use and Outcome of DCD Livers
Background/Aim: Donation after circulatory death (DCD) liver transplants (LTs) are increasingly performed due to organ shortage. Graft survival rates for DCD LTs are inferior to…2013 American Transplant Congress
Predicting Survival and Recurrence Following Liver Transplantation for Hepatocellular Carcinoma: National Analysis of Clinical and Pathologic Staging
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Research, UNOS, Richmond, VA
IntroductionAnalysis of longer term survival following liver transplantation for hepatocellular carcinoma (HCC-LT) has been limited to single center series or registry analyses lacking pathologic detail.MethodsA…2013 American Transplant Congress
Impact of the Revised Lung Allocation Score on Heart-Lung Candidates
Introduction: The lung allocation score (LAS) has been used since 2005 to rank US lung transplant candidates for access to transplant. A revised LAS (LAS-R)…2013 American Transplant Congress
Assessment of the Time to Therapeutic Tacrolimus Levels and the Incidence of Rejection in Heart Transplant Patients
St.Luke's Episcopal Hospital, Houston, TX; Texas Heart Institute, Houston, TX
Purpose: To assess the relationship between the time to achieve consecutive therapeutic tacrolimus levels and the incidence of rejection to optimize tacrolimus dosing in cardiac…2013 American Transplant Congress
Status 1A Utilization for Heart Transplant Candidates with Ventricular Assist Devices (VADs)
Background: OPTN policy 3.7.3(a)(i) allows heart transplant candidates with ventricular assist devices (VAD) to be listed as Status 1A for 30 days at any time…2013 American Transplant Congress
Has the VA Found a Way To Reduce Racial Disparities in Kidney Transplant Evaluation? Preliminary Results from the National VA Kidney Transplant Study
End-stage kidney disease is more common in African Americans (AA) and other minorities (OM) (e.g., Hispanic/Latinos) than Whites (WH). Reports from national data indicate that…2013 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Follow-Up Results of the HERAKLES Trial at Month 24
HERAKLES Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimens 2years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2013 American Transplant Congress
Donor Age and Ischemia Time Are Independent Factors Affecting Graft Survival after En-Bloc Kidney Transplantation from Pediatric Donors
Introduction:En-bloc kidney transplantation in adult recipients using organs from pediatric donors remains controversial. The aim of the study was to investigate short- and long-term outcome…2013 American Transplant Congress
Multicenter Valdiation of Urinary Biomarkers in Kidney Transplantation: Urinary CXCL9 Protein Correlates with Acute Rejection and Deterioration of Kidney Function
Noninvasive biomarkers to diagnose and/or predict outcomes in kidney transplant recipients are needed to assess post-transplant risk and ultimately to guide management of immunosuppression. Results…
American Transplant Congress abstracts